"Design, Rationale and Baseline Characteristics of the Randomized Double-blind Phase II Clinical Trial of Vidofludimus calcium (IMU-838) in Relapsing-Remitting Multiple Sclerosis (4558)." Neurology
94.15 Supplement
(2020):
4558.
Web. 21 Mar. 2023.
Advertisement